Merck & Co., Inc.
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$148.36−1.16 (-0.78%)
Close on Nov 2, 2026Market cap $366.03BP/E 118.7Yield 2.21%
Merck Organon by Quarter
Organon — Vtama (tapinarof cream, acquired via Dermavant Q4 2024) International sales ($M) ($M)
Merck Organon: $1,000,000M in Q2 2026, down 50.0% from a year earlier.
Latest, Q2 2026
1,000,000
Period ended Jun 30, 2026
Change on a year earlier
-50.0%
2,000,000 in Q2 2025
History
10 quarters
Since Q1 2024
Sources
7
Documents cited below
Where the Q2 2026 figure comes from
Source: Organon & Co. SEC Filing (0001628280-26-051230) ↗
Reported in Organon & Co. Form 10-Q / 10-K (CIK 0001821825).
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Organon — Vtama (tapinarof cream, acquired via Dermavant Q4 2024) International sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 1,000,000 | -50.0% | Organon & Co. SEC Filing (0001628280-26-051230) ↗ |
| Q1 2026 | Mar 31, 2026 | 2,000,000 | -50.0% | Organon & Co. SEC Filing (0001628280-26-029532) ↗ |
| Q4 2025 | Dec 31, 2025 | 8,000,000 | +700.0% | Organon & Co. SEC Filing (0001628280-26-011125) ↗ |
| Q3 2025 | Sep 30, 2025 | 3,000,000 | – | Organon & Co. SEC Filing (0001628280-25-050795) ↗ |
| Q2 2025 | Jun 30, 2025 | 2,000,000 | – | Organon & Co. SEC Filing (0001821825-25-000066) ↗ |
| Q1 2025 | Mar 31, 2025 | 4,000,000 | – | Organon & Co. SEC Filing (0001821825-25-000023) ↗ |
| Q4 2024 | Dec 31, 2024 | 1,000,000 | – | Organon & Co. SEC Filing (0001821825-25-000006) ↗ |
| Q3 2024 | Sep 30, 2024 | 0 | – | Organon & Co. SEC Filing (0001628280-25-050795) ↗ |
| Q2 2024 | Jun 30, 2024 | 0 | – | Organon & Co. SEC Filing (0001821825-25-000066) ↗ |
| Q1 2024 | Mar 31, 2024 | 0 | – | Organon & Co. SEC Filing (0001821825-25-000023) ↗ |
Cite this data
StockData. (2026). Merck Organon ($M), quarterly Q1 2024–Q2 2026 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/ogn-vtama-intl
See every metric in the Merck KPI table. Data updated Oct 26, 2026.